Article Text

other Versions

PDF
Original research
Transarterial embolization of intractable nasal and oropharyngeal hemorrhage using liquid embolic agents
  1. Seth B Hayes1,
  2. Jeremiah N Johnson1,
  3. Zachary Most1,
  4. Mohamed Samy Elhammady1,
  5. Dileep Yavagal1,2,
  6. Mohammad Ali Aziz-Sultan1,3
  1. 1Department of Neurosurgery, University of Miami, Miller School of Medicine, Miami, Florida, USA
  2. 2Department of Neurology, University of Miami, Miller School of Medicine, Miami, Florida, USA
  3. 3Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA
  1. Correspondence to Dr Mohammad Ali Aziz-Sultan, Department of Neurosurgery, Brigham and Women's Hospital, 75 Francis Street, PBB-311, Boston, MA 02115, USA; sultan{at}partners.org

Abstract

Introduction Intractable hemorrhage of the nasal or oropharyngeal cavities can be life threatening, and endovascular embolization is one of the few effective treatments for severe recurrent bleeds. Traditionally, embolic particles have been used for transarterial embolization.

Objective To investigate the safety and efficacy of a less commonly performed treatment—namely, feeding artery occlusion with liquid embolic agents.

Methods We retrospectively reviewed our neurointerventional database for patients who had undergone transarterial embolization for intractable nasal and oropharyngeal hemorrhage with Onyx, N-butyl-2 cyanoacrylate (n-BCA) glue, or both, at our institution over a 5-year period from 2008 to 2013.

Results Forty-six patients who underwent a total of 51 procedures met the inclusion criteria. Causes of hemorrhage included neoplasm n=35 (68.6%), trauma n=12 (23.5%), and idiopathic n=4 (7.9%). The bleeding was oropharyngeal in 66.7%, nasal in 29.4%, and 3.9% originated from both sites. Embolic agents used were n-BCA in 26 cases (51.0%), Onyx in 22 cases (43.1%), and both agents in three cases (5.9%). Mean total procedural time was 93.1 min (range 34–323 min), and mean fluoroscopy time was 39.1 min (10– 121 min). Mean follow-up time was 7.4 months (0.25–36 months). Five of the 46 patients (10.9%) required re-embolization and one (2.0%) rebled during the same hospital stay. One periprocedural cardiovascular adverse event occurred that was unrelated to the embolic agent used, but no other complications were seen.

Conclusions Transarterial embolization with n-BCA or Onyx is a safe and effective treatment for patients with intractable nasal and oropharyngeal hemorrhage. Further prospective studies are warranted to confirm these findings.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.